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Human cytomegalovirus (HCMV) rewires
cellular lipid metabolism. Purdy et al.
show that fatty acid elongase 7 is strongly
upregulated by HCMV—via viral
modulation of mTOR-SREBP1—to
produce saturated very-long-chain fatty
acids. This elongation is important for
virion membrane production of this
enveloped virus, as well as for viral
replication.
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Human cytomegalovirus (HCMV) infection rewires
host-cell metabolism, upregulating flux from glucose
into acetyl-CoA to feed fatty acid metabolism,
with saturated very-long-chain fatty acids (VLFCAs)
required for production of infectious virion progeny.
The human genome encodes seven elongase en-
zymes (ELOVL) that extend long-chain fatty acids
into VLCFA. Here, we identify ELOVL7 as pivotal for
HCMV infection. HCMV induces ELOVL7 by more
than 150-fold. This induction is dependent on
mTOR and SREBP-1. ELOVL7 knockdown or mTOR
inhibition impairs HCMV-induced fatty acid elon-
gation, HCMV particle release, and infectivity per
particle. ELOVL7 overexpression enhances HCMV
replication. During HCMV infection, mTOR activity
is maintained by the viral protein pUL38. Expression
of pUL38 is sufficient to induce ELOVL7, and pUL38-
deficient virus is partially defective in ELOVL7 in-
duction and fatty acid elongation. Thus, through its
ability to modulate mTOR and SREBP-1, HCMV in-
duces ELOVL7 to synthesize the saturated VLCFA
required for efficient virus replication.
INTRODUCTION
Human cytomegalovirus (HCMV), a b-herpes virus, is a widely
dispersed enveloped virus that establishes a life-long persistent
infection in greater than 60% of the world population (Mocarski
et al., 2007). HCMV is a major cause of birth defects, an oppor-
tunistic infection in HIV-1/AIDS patients, and a life-threatening
post-transplant complication in allograft recipients (Britt, 2008).
In addition, it has been associated with glioblastoma and other
cancers (Cobbs, 2013; Cobbs et al., 2002), cardiovascular dis-
ease (Streblow et al., 2008), and immune senescence (Moss,
2010).
To meet their needs, viruses modulate specific cellular meta-
bolic networks, but little is known about howmost viruses exploit
cellular metabolic and lipid environments. HCMV provides aCemodel system for studying how viruses rewire cellular physiology
because a global change in metabolism of infected cells occurs
during replication (Chambers et al., 2010; Munger et al., 2008;
Rabinowitz et al., 2011; Vastag et al., 2011). HCMV increases
glucose uptake (Munger et al., 2006; Yu et al., 2011), glycolytic
and TCA fluxes (Munger et al., 2008), as well as lipid metabolism
(Koyuncu et al., 2013; Sanchez and Dong, 2010; Yu et al., 2012).
HCMV, like all enveloped viruses, depends on its host cells to
provide the lipids required to build its envelope. Previously we
reported that infected cells use carbons derived from glucose
to synthesize very-long-chain fatty acids (VLCFAs), which are
required for efficient viral replication (Koyuncu et al., 2013).
Fatty acid (FA) synthesis is initiated by FA synthase (FAS),
forming long-chain FAs up to 16 carbons in length (C16) by con-
necting carbons, two at time, using malonyl-CoA as a substrate.
This process is controlled by the synthesis of malonyl-CoA from
acetyl-CoA by acetyl-CoA carboxylase 1 (ACC-1). The product
of FAS is the 16-carbon FA palmitate (C16:0; the number
following the colon represents the number of double bonds in
the FA). Palmitate can be processed further to make a longer
chain or desaturated to introduce a double bond among the
carbons in the tail. In human cells, longer FAs are made by one
or more of the seven elongases (ELOVL1–7), again by using
two-carbon units from malonyl-CoA.
ELOVLs are important for various biological processes, such
as proper development (Harkewicz et al., 2012; Li et al., 2007).
They may also play a role in disease processes; for example,
ELOVL7 has been implicated in the growth of prostate tumor
cells (Tamura et al., 2009). ELOVLs show substrate preference,
depending on the chain length and degree of saturation of the
FA chain to be elongated. In general, saturated FAs can be elon-
gated by ELOVL1, 3, 4, and 7 (Ohno et al., 2010; Tamura et al.,
2009), monounsaturated FAs by ELOVL1, 3, 5, 6, and 7 (Kita-
zawa et al., 2009; Ofman et al., 2010; Ohno et al., 2010), and
polyunsaturated FAs by ELOVL 2, 4, and 5 (Harkewicz et al.,
2012; Leonard et al., 2002; Ohno et al., 2010). ELOVL1, 4, 5,
and 6 are ubiquitously expressed, whereas the others are more
tissue tropic (Ohno et al., 2010). The expression of ELOVLs is
controlled by transcription factors such as sterol regulatory-
element-binding proteins (SREBPs), but it is likely that cells
also use additional mechanisms to control their expression and
activity (Jakobsson et al., 2006; Moon et al., 2001).ll Reports 10, 1375–1385, March 3, 2015 ª2015 The Authors 1375
Figure 1. HCMV Induces Fatty Acid Elonga-
tion to Produce VLCFAs that Are Incorpo-
rated into the Virion Envelope
(A) Schematic of pathway from glucose to fatty
acid elongation. The straight line down from
glucose indicates glycolysis, and the circle in-
dicates the TCA cycle. Fatty acid elongases
(ELOVLs) use malonyl-CoA as a substrate to
elongate shorter fatty acids.
(B) Incorporation of labeled carbons from
13C-glucose into saturated FAs in purified virions.
Virions were isolated from cells grown in serum-
free DMEM containing all glucose U-13C labeled.
For each FA species, the data are reported as the
percentage that contains at least one 13C-labeled
two-carbon unit.
(C) The labeling pattern of C26:0 from virions
grown as in (B).
All data are represented as mean ± SEM of three
independent experiments. See also Figure S1.The requirement for FA elongation is a poorly understood
aspect of HCMV biology. Here, we examine the role of ELOVLs
in HCMV replication, identifying a pivotal role specifically for
ELOVL7. Metabolic tracers were used to establish that HCMV
infection induces the ELOVL7-dependent synthesis of lipids
with VLCFA tails that are subsequently used to build the virion
envelope. ELOVL7 was found to be essential for the efficient
release of viral particles and to the infectivity of cell-free prog-
eny. Additionally, we demonstrate that HCMV, in part via
pUL38, strongly induces the expression and activity of ELOVL7
by manipulating the mammalian target of rapamycin kinase
(mTOR) and SREBP1. Our results illustrate that HCMV com-
mandeers multiple cellular mechanisms (e.g., kinase and tran-
scriptional activity) to ensure ELOVL7 produces saturated
VLCFAs that are required to build a properly functioning viral
envelope.
RESULTS
Glucose-Derived Two-Carbon Units Contribute to the
Virion Envelope via Elongation
Enveloped viruses, such as HMCV, either (1) derive the lipids to
build their envelope from those present in the host cell prior to
infection and/or (2) induce the cell to synthesize the required
lipids during the viral replication cycle. HCMV infection of fibro-
blast cells results in upregulated FA elongation flux, resulting in
a several-fold increase in VLCFAs in the host cell after infection
with HCMV at a high MOI (three infectious units [IUs] per cell;
Koyuncu et al., 2013). We hypothesized that these newly synthe-
sized saturated VLCFAs are used to build virion lipids. This hy-
pothesis was directly tested using uniformly labeled 13C-glucose
as a metabolic tracer. Flow of carbons derived from glucose into
FA synthesis and elongation results in labeling of the FA hydro-
carbon tails (Figure 1A). The experiments were performed under
serum-free conditions in order to eliminate contaminating sour-
ces of FAs from FBS. Lipids extracted from the biological sam-1376 Cell Reports 10, 1375–1385, March 3, 2015 ª2015 The Authorsples were saponified to release the FA tails, enabling the analysis
of these tails by LC-MS. Most C16:0 and C18:0 FA tails in the
viral envelope were unlabeled (Figure 1B). In contrast, longer
chains were predominantly labeled with more than 80% of the
measured C26:0 containing at least one 13C-labeled two-carbon
unit. Evaluation of unsaturated FA revealed that virion FA labeling
was greatest with increasing chain length and a lower degree of
saturation (Figure S1A). The labeling of FAs from virions was
compared to FA isolated from uninfected and infected
fibroblasts. Consistent with our previous work, viral infection
increased 13C incorporation into host cell FAs, particularly the
VLCFAs (Koyuncu et al., 2013; Figure S1A). Overall, the extent
of labeling in the virions was similar to infected cells, with most
extensive labeling of saturated VLCFAs (Figure S1A). The obser-
vation that saturated FAs are enriched in the viral envelope in
comparison to unsaturated FAs (Figure S1B) further underscores
their importance to HCMV replication.
Next, we evaluated the isotope-labeling pattern of the virion
VLCFAs. FAS generates one C16:0 LCFA using two-carbon units
from one acetyl-CoA and seven malonyl-CoAmolecules. The re-
sulting C16 FA can be elongated by ELOVLs using two-carbon
units derived from malonyl-CoA. In the case of C26:0, de novo
synthesis would result in 12–26 labeled carbons, depending on
the extent to which the acetyl-CoA/malonyl-CoA pools are
labeled, whereas the incorporation of ten or fewer 13C carbons
would demonstrate that the VLCFAs are made by elongation of
preexisting FAs. In virions, the C26:0 contained ten or fewer
13C-labeled carbons, demonstrating that most of the VLCFAs
aremade by ELOVLs extending shorter-chained FAs that existed
in the cell prior to infection (Figure 1C). The C26:0 labeling
pattern in the virion was similar to that of infected cells (Koyuncu
et al., 2013; Figure S1C). Thus, induction of malonyl-CoA synthe-
sis from glucose by HCMV contributes to the virion envelope via
saturated FA elongation.
To further define the relationship between HCMV replication
and FA elongation, the 13C labeling of FAs in cells infected at
Figure 2. Fatty Acid Elongase 7 Is Strongly Induced by HCMV and
Required for Efficient Production of Infectious Progeny
(A) ELOVL1–7 mRNA levels during the course of HCMV replication. MRC-5
fibroblasts infected at 3 IU/cell were compared to mock-infected cells for
ELOVL1–6. The (*) denotes that, because the ELOVL7 transcript was not
detectable in uninfected cells, the ELOVL7 data are reported as fold change
from 4 hpi.
(B) HCMV replication in MRC-5 fibroblasts with shRNA knockdown of
ELOVL1–7 (compared to non-targeting [NT] sequence control). Knockdown
cells were infected at 0.5 IU/cell, and at 96 hpi, the medium was assayed for
infectious progeny. (*p < 0.05; t test).
All data are represented as mean ± SEM of at least three independent
experiments. See also Figure S2.various multiplicities was examined. Fibroblast cells infected
at multiplicity as low as 0.5 IU per cell showed an increased
labeling of saturated FAs, with the overall labeling of VLCFAs
dependent on the amount of input virus (Figure S1D). Similarly,
the cellular concentration of saturated VLCFA, especially those
of 26 carbons or longer, was dependent on the MOI (Fig-
ure S1E). These observations reinforce the conclusion that
HCMV induces FA elongation. Collectively, these data demon-
strate that, during viral replication, FA elongation is upregulated
to build lipids containing saturated VLCFA tails to be used for
the viral envelope.CeElongation Catalyzed by ELOVL7 Is Required for
Efficient HCMV Replication
We were curious which of the seven known ELOVLs contribute
to the observed FA elongation during HCMV infection. We first
determined how the expression of each ELOVL was altered by
HCMV. The mechanisms controlling ELOVL activity have not
been thoroughly studied, but their activity is regulated at least
in part at the level of gene expression (Jakobsson et al., 2006;
Wang et al., 2006); thus, the RNA levels of each ELOVL was
tested following infection at a multiplicity of 3 IU/cell. By 48 hr
post-infection (hpi), the expression of all seven ELOVLs was at
least 2-fold increased (Figure 2A), confirming findings of a previ-
ously performed screen (Koyuncu et al., 2013). The expression of
some ELOVLs continued to increase as replication progressed.
Of note, ELOVL7 levels were below a level that could be reliably
detected in uninfected cells; however, its RNA was observed at
low levels in two out of three experiments in the 4-hpi samples.
Remarkably, ELOVL7 RNA levels increased over 150-fold from
the level observed at 4 hpi; thus, compared to uninfected cells,
HCMV-infected cells express R150-fold greater amounts of
ELOVL7 mRNA.
To test which, if any, of the seven ELOVLs is required for
viral replication, an shRNA knockdown strategy was employed.
Three shRNA clones targeting each ELOVL were used to
generate a stable knockdown inMRC-5 fibroblasts. Viral replica-
tion was decreased by all clones tested for ELOVL5 and 7 and by
one clone of ELOVL1 (Figure S2A). To increase the knockdown
efficiency in infected cells and to counteract the induction of
ELOVLs by HCMV, we pooled the three clones per ELOVL and
generated knockdown cells that received each lentivirus at a
multiplicity of at least 3 IU/cell. Using this pooling method, a
greater than 60% knockdown of mRNA at 96 hpi was achieved
for all ELOVLs; most ELOVL mRNA levels, including ELOVL7,
were decreased by 80%–90% (Figure S2B). Under these condi-
tions, the decrease in ELOVL5 and 7 resulted in a marked reduc-
tion in the production of extracellular infectious progeny (Figures
2B and S2C). Knockdown of ELOVL1 resulted in a modest
reduction (Figure 2B), but this is likely due to the knockdown
affecting the health of the host cell because these fibroblasts
had a severe growth defect (Figure S2D). Thus, the shRNA
knockdown experiments demonstrate that ELOVL5 and 7 are
required for efficient HCMV replication.
Because ELOVL7 is reported to elongate saturated VLCFAs,
whereas ELOVL5 is thought to produce PUFAs (Leonard et al.,
2002; Tamura et al., 2009), and given the dramatic increase in
ELOVL7 RNA levels caused by HCMV infection, we hypothe-
sized that ELOVL7 activity is essential for the observed enrich-
ment in saturated VLCFAs in infected cells and virions. Thus,
we focused on saturated FAs and ELOVL7.
ELOVL7 Is Essential for Virus-Induced VLCFA Synthesis
As expected from theRNA results, ELOVL7 proteinwas detected
at a low level in uninfected fibroblasts but strongly increased dur-
ing the course of infection (Figure 3A). ELOVL7 knockdown cells
were used to evaluate whether the loss of this enzyme altered
the kinetics of viral replication. The replication of HCMV can be
divided into three phases: immediate-early (viral gene expression
that occurs following viral entry), early (genes expressedll Reports 10, 1375–1385, March 3, 2015 ª2015 The Authors 1377
Figure 3. ELOVL7 Synthesizes Fatty Acids
Required for Virion Infectivity
(A) ELOVL7 protein level during HCMV replication
(3 IU/cell). An immediate-early protein (pUL122) is
shown as a marker of viral replication.
(B) Kinetics of the HCMV replication cycle in
ELOVL7 knockdown cells (compared to NT control
cells). Immediate-early protein 1 (pUL123; IE1),
early proteins pUL44 and pUL26, leaky-late protein
pUL83, and late pUL99 protein were examined.
(C) C26:0 labeling pattern in knockdown cells
grown in DMEM without fetal bovine serum with all
glucose U-13C labeled. Cells were harvested at
72 hpi following infection at 1 IU/cell.
(D) Saturated FA labeling in cells grown under la-
beling conditions described in (C).
(E) Concentration of saturated FAs in cells grown in
serum-free DMEM (72 hpi; 1 IU/cell).
(F) The release of infectious progeny, DNA-con-
taining particles, and particle-to-infectious prog-
eny ratio (1 IU/cell). Left: infectious progeny as
measured by TCID50 (left). Total (infectious and
non-infectious) cell-free viral particles were deter-
mined by the number of genomes (viral DNA) per ml
of medium collected from the cells (middle). The
particle-to-IU ratio was also compared (right).
All data are represented as mean ± SEM of three
independent experiments. (*p < 0.05; **p < 0.01;
t test).subsequently to immediate-early genes and prior to viral DNA
replication), and late (those that require viral DNA replication). In
these experiments, ELOVL7 protein knockdown was maintained
for 120 hr following infection (Figure 3B). Although the early pro-
teins assayed (pUL44 and pUL26) accumulated with a slight
delay, all viral proteins, including late viral proteins (pUL99 and
pUL83) accumulated to normal levels in ELOVL7-deficient cells.
Viral DNA synthesis was lower, but not significantly altered, in
knockdown cells as predicted because the expression of the
late viral proteins is chiefly dependent on DNA replication (Fig-
ure S2E). Altogether, these data suggest that the decrease in
the release of infectious progeny by the knockdown cells is due
to a defect downstream of late protein synthesis.
The ability of ELOVL7 knockdown cells to produce saturated
FAs during HCMV infection was examined using 13C-glucose.
Knockdown of ELOVL7 substantially reduced the labeling of
C26:0 and other VLCFAs (Figures 3C and 3D). This reduced
production resulted in a selective depletion of VLCFA tails,1378 Cell Reports 10, 1375–1385, March 3, 2015 ª2015 The Authorsespecially of C26:0, the VLCFA that
is most dramatically increased during
viral replication (Figures 3E and S2G).
The increasing extent of depletion with
greater FA length is consistent with the
synthesis of the longer VLCFA chains
requiring more elongation steps (e.g.,
five for C26:0 versus two for C20:0)
and/or with ELOVL7 being particularly
important for the later steps. Thus, during
HCMV infection, ELOVL7 is required to
produce saturated VLCFA tails.To evaluate the consequence of deficiency of such VLCFAs
on viral replication, we quantitated the number of infectious par-
ticles released by control and ELOVL7 knockdown cells by
TCID50. Infectious particles released into the medium at 96 and
120 hpi were decreased by a factor of 20 in the knockdown
cells (Figure 3F, left). A partial recovery of infectivity was restored
by adding one product of ELOVL7, C26:0, to knockdown cells,
demonstrating that the loss of saturated VLCFA is responsible
for the decrease in infectivity (Figure S2F); a more complete
recovery of infectivity may require the addition of other VLCFAs,
each at a proper concentration, or might require subcellular
localization of the VLCFAs, which is not achieved via exogenous
feeding. Interestingly, adding C26:0 to control cells caused ami-
nor loss, 2-fold, of infectivity, suggesting that an optimal level
(and/or localization) of saturated VLCFAs is required for viral
replication (Figure S2F).
To examine whether this decreased activity reflected a failure
to release particles or defective infectivity of the particles that are
Figure 4. HCMV Replication Is Enhanced by
Overexpression of ELOVL7
(A) ELOVL7 protein levels in uninfected MRC-5
fibroblast cells following ELOVL7 overexpression
using pLVX-lentiviral stable expression (GFP-
expressing cells were used as a control).
(B) Kinetics of the HCMV replication cycle (1 IU/
cell).
(C) C26:0 labeling pattern (1 IU/cell; 72 hpi).
(D) Saturated FA labeling (1 IU/cell; 72 hpi).
(E) Concentration of saturated FAs (1 IU/cell;
72 hpi).
(F) Production of cell-free infectious virus (1 IU/cell).
All data are represented as mean ± SEM of three
independent experiments. (*p < 0.05; **p < 0.01;
t test).released, we measured the particle number by determining the
amount of encapsidated viral DNA released by cells. The particle
number was substantially reduced by ELOLV7 knockdown, but
not asmuch as the number of infectious progeny (Figure 3F, mid-
dle). The particle-to-IU ratio released by control cells was 100
particles per virion at both time points assayed; in contrast, the
ratio was400 and900 particles per virion in knockdown cells
at 96 and 120 hpi, respectively (Figure 3F, right). Thus, ELOVL7 is
required both for particle release and for infectivity of the
released particles.
Overexpression of ELOVL7 Enhances Production of
Infectious HCMV Progeny
Wehave demonstrated the ELOVL7 is necessary for viral replica-
tion. To further monitor the ability of ELOVL7 to optimize HMCV
infectivity, cells stably overexpressing ELOVL7 were generatedCell Reports 10, 1375–13by lentiviral transduction (Figure 4A). Viral
protein expression in ELOVL7-overex-
pressing cells was indistinguishable from
that in control cells stably expressing
GFP, suggesting that increased levels of
ELOVL7 do not affect viral protein expres-
sion and replication kinetics (Figure 4B).
The overall incorporation of 13C from
labeled glucose into saturated VLCFAs
was enhanced by the overexpression of
ELOVL7, demonstrating increased elon-
gation activity in these cells (Figures 4C
and 4D), which resulted in higher concen-
trations of the associated saturated
VLCFA products (Figure 4E). A significant
concentration increase was seen for FAs
of 20 carbons and longer. Thus, ELOVL7
is sufficient to produce significant quanti-
ties of these FAs, although the ELOVL7
knockdown data suggest that it is neces-
sary primarily for only those of 24 or
more carbons (Figures 2D and 2E),
perhaps because other elongases can
also produce C20 or, in the context of
overexpression, ELOVL7 releases C20 af-ter elongating C16–C18. Importantly, ELOVL7 overexpression
enhanced the ability of host cells to support viral replication, as
indicated by a greater than 2-fold increase in the release of infec-
tious progeny compared to controls cells expressing GFP (Fig-
ure 4F). These experiments support the view that the ability of
host cells to generate lipids with saturated VLCFAs is a critical
factor that limits HCMV replication in fibroblasts. Overall, we
conclude that ELOVL7 plays an important role in HCMV replica-
tion by providing the VLCFAs necessary to build infectious
virions.
Viral Protein pUL38 Activates mTOR and Thereby
Induces ELOVL7
Our results establish that HCMV strongly induces the expression
of ELOVL7 to generate VLCFAs required to form virions. To
probe the mechanism underlying the manipulation of ELOVL785, March 3, 2015 ª2015 The Authors 1379
Figure 5. HCMV-Induced mTOR and
SREBP1 Activity Is Required for Lipid
Remodeling
In all panels, cells were treated with Torin 2 to
inhibit mTOR or DMSO as a control.
(A) Torin 2 blocked HCMV infectivity (bars) at
various concentrations without altering cell sur-
vival of uninfected cells (circles).
(B) ELOVL7 and pUL123 protein levels. AKT and
rpS6 are shown as controls to verify mTOR inhi-
bition.
(C) C26:0 labeling pattern under 0.1 mM Torin 2
treatment (3 IU/cell; 72 hpi).
(D) Saturated FA labeling under 0.1 mM Torin 2
treatment (3 IU/cell; 72 hpi).
(E) Concentration of saturated FAs under 0.1 mM
Torin 2 treatment (3 IU/cell; 72 hpi).
(F) mRNA levels of ELOVL7 in SREBP1 and
SREBP2 knockdown cells. FAS and HMGCR
levels were used tomonitor the decrease in activity
of SREBP1 and 2, respectively.
(G) Maturation of SREBPs in infected cells treated
with various mTOR inhibitors (0.1 mM Torin 2, 1 mM
PP242, and 0.5 mM INK128).
All data are represented as mean ± SEM of three
independent experiments (*p < 0.05; **p < 0.01;
t test). See also Figure S3.by HCMV, we examined the role of mTOR in the ELOVL7 expres-
sion. mTOR complex 1 (mTORC1) kinase activity is required to
maintain active translation (Mamane et al., 2006), and the kinase
also controls key aspects of lipid metabolism via several mech-
anisms, including SREBP-1 activation (Laplante and Sabatini,
2009; Lewis et al., 2011). HCMV induces stress response
signaling that would normally block mTOR activity. However,
HCMV encodes a viral protein, pUL38, which binds and antago-
nizes the tuberous sclerosis protein complex, a suppressor of
mTOR (Moorman et al., 2008). Through this and additional mech-
anisms, the kinase is maintained in an active state following
infection (Clippinger and Alwine, 2012; Kudchodkar et al.,
2004, 2006; Moorman et al., 2008; Moorman and Shenk, 2010).
To determine the importance of mTOR activity in HCMV repli-
cation and ELOVL7 induction, cells were treated with Torin 2, a1380 Cell Reports 10, 1375–1385, March 3, 2015 ª2015 The Authorsselective and potent inhibitor of mTORC1
and mTORC2 (Liu et al., 2011a). Torin 2
blocked HCMV replication without any
discernable cytotoxic effects (Figure 5A).
The ability of Torin 2 to inhibit mTOR
activity was evaluated by examining the
phosphorylation of two known targets of
mTOR: ribosomal protein S6 and AKT.
Phosphorylation of both targets was
completely blocked by 50 nM Torin 2;
phosphorylation of AKT was decreased
by infection at the late stages assayed
consistent with its decrease after 24 hpi
(Kudchodkar et al., 2004) (Figure 5B). Inhi-
bition of mTOR resulted in a slight reduc-
tion in the accumulation of an HCMV im-mediate-early protein (pUL123; IE1) at 48 and 72 hpi, similar to
the results previously reported for Torin 1 treatment, a related
mTOR inhibitor (Moorman and Shenk, 2010). Treatment with
Torin 2 markedly reduced the HCMV-induced upregulation of
ELOVL7 transcript (Figure S3C) and protein (Figure 5B). Similar
results were observed with two additional—but structurally
distinct—mTOR inhibitors (Figures S3A and S3B). Although
drug treatment decreased ELOVL7 expression, a restoration of
viral replication was not observed in cells expressing ELOVL7
cells, likely due to the polymorphic function of mTOR during
HCMV infection (Figure S3D). Moreover, Torin 2 treatment re-
sulted in a major reduction in FA elongation when compared to
DMSO-treated control cells, as evident by less labeling of
C26:0 (Figure 5C) and other long- and very-long-chain saturated
FAs (Figure 5D). Unlike the ELOVL7 knockdown experiments
Figure 6. Viral pUL38 Protein Drives ELOVL7
Expression
(A) ELOVL7 protein level in uninfected cells ex-
pressing viral protein pUL38 (or GFP as a control)
using pLVX-lentiviral stable expression.
(B) ELOVL7 protein expression in cells infected with
WT (AD169) or ADdlUL38, a mutant virus lacking the
UL38 gene (3 IU/cell; 48 hpi).
(C) C26:0 labeling pattern (3 IU/cell; 48 hpi).
(D) Saturated FA labeling (3 IU/cell; 48 hpi).
(E) Concentration of saturated FAs (3 IU/cell; 48 hpi).
All data are represented as mean ± SEM of three
independent experiments (*p < 0.05; **p < 0.01;
t test). See also Figure S4.(Figure 3), Torin 2 treatment altered the labeling of shorter-
chained FAs, suggesting that mTOR inhibition is also altering
the activity of other enzymes involved in FAmetabolism. Consis-
tent with a reduction of elongase activity observed under labeling
conditions, Torin 2 treatment decreased the concentrations of
the VCLFA species important for viral replication (Figure 5E).
These data demonstrate that, in addition to its other roles (e.g.,
in protein translation), mTOR is important for lipid metabolism
during HCMV infection.
mTOR may control the expression of ELOVL7 by influencing
thematuration and activity of SREBPs. SREBPs are transcription
factors well known to regulate the expression of genes involved
in FAmetabolism (Ye and DeBose-Boyd, 2011), and HCMV stim-
ulates the maturation of SREBP1 and 2 (Spencer et al., 2011; Yu
et al., 2012). To investigate this further, we examined the levels of
ELOVL7 in host cells in which SREBP1 or SREBP2 levels were
reduced using shRNA. The level of each transcription factor
was reduced by approximately 80% compared to non-targeting
shRNAcontrol cells (Figure 5F). RNA for ELOVL7was reduced by
2-fold in cells with reduced SREBP1; this reductionwas similar to
the RNA level of a known gene regulated by SREBP1, FAS (Ye
and DeBose-Boyd, 2011). In contrast, only a 20% reduction in
ELOVL7 RNA level was observed with knockdown of
SREBP2—compared to a 2-fold decrease in the RNA level of a
SREBP2-regulated gene, HMG-CoA reductase—demonstrating
that SREBPs, particularly SREBP1, regulates the level of ELOVL7
in HCMV-infected cells. Because the mTOR inhibitor Torin 1 hasCell Reports 10, 1375–13previously been shown to impact
SREBP2 maturation in HCMV-infected
cells (Spencer et al., 2011), we examined
the level of mature SREBPs in cells treated
with three different mTOR inhibitors (Fig-
ure 5G). As expected, maturation of
SREBP2 was dramatically reduced by
each inhibitor. Moreover, the level of
mature SREBP1 was reduced upon
mTOR inhibition, thereby establishing a
pathway via mTOR and SREBP1 by which
HCMV induces ELOVL7 and FA elongation.
To evaluate more directly whether the
HCMV-encoded, mTOR-activating pUL38
protein contributes to ELOVL7 expres-
sion, we generated uninfected cells thatstably expressed the protein. pUL38 alone increased the level
of ELOVL7 protein compared to uninfected cells, but not to the
level observed in infected fibroblasts; however, this observation
demonstrates that it has the ability to control ELOVL7 expression
independent of other virus-encoded factors (Figure 6A).
Although pUL38 expression in uninfected cells induced ELOVL7,
it was not sufficient to increase FA elongation, presumably due to
the lack of upregulation of upstream metabolic events (Fig-
ure S4A). To further probe the role of pUL38 in the expression
of ELOVL7, cells were infected with a mutant virus, ADdlUL38,
which lacks the UL38 gene (Terhune et al., 2007). Because cells
infected with virus containing a UL38 deletion show dramatic cell
death at 72 hpi (Terhune et al., 2007), we limited our analysis to
48 hpi. The mutant induced ELOVL7 expression, but not as
strongly as wild-type virus (Figure 6B). Thus, although pUL38 is
not the sole mechanism by which HCMV induces ELOVL7,
pUL38 is necessary for its full expression.
Consistent with a loss of ELOVL7 expression, we observed a
substantial reduction in elongation of C26:0 and other saturated
FA in ADdlUL38-infected cells at 48 hpi when compared to cells
infected with WT virus (Figures 6C and 6D). The concentration of
C26:0 was decreased by >2-fold in ADdlUL38-infected cells,
whereas those of shorter lengths were less affected (Figure 6E).
Similar to WT virus, ADdlUL38 replication was enhanced—but
less than 2-fold—in ELOVL7-overexpressing cells at 120 hpi
(Figure S4B compared to Figure 4F). Additionally, ELOVL7 parti-
cles released by ADdlUL38-infected cells had a similar85, March 3, 2015 ª2015 The Authors 1381
Figure 7. Schematic of Mechanisms by which HCMV Induces
Lipidome Remodeling by ELOVL7disruption in the particle-to-IU ratio as those released by
ELOVL7 knockdown cells infected with WT virus (Figures S4C
and 3F). In sum, these data establish that pUL38, through its abil-
ity to control mTOR activity, aids in the synthesis of VLCFAs that
are required to build infectious virions.
DISCUSSION
FA metabolism is an important determinant for the replication of
diverse viruses. Cells infected with another herpes virus, Kapo-
si’s-sarcoma-associated virus, exhibited elevated FA synthesis
compared to uninfected endothelial cells (Delgado et al., 2012).
Some RNA viruses, such as hepatitis C and rift valley fever
viruses, remodel lipids during their assembly process (Moser
et al., 2012; Nasheri et al., 2013; Petersen et al., 2014). In the
case of dengue virus, FAS is relocalized to the location of viral
replication so that C16:0 is produced at the intracellular site
where the virus utilizes it (Heaton et al., 2010). Most previous
studies have examined the role of FAS. The study described
here highlights the importance of FA elongases, specifically
ELOVL7, during viral replication.
HCMV instructs host cells to build lipids enrichedwith saturated
VLCFAs that are required to construct a properly functioning
virion. VLCFAs could contribute to the organization of lipid-
embedded virion envelope proteins or to membrane dynamics
during entry or egress of virions. Entry, assembly, and egress of
virions are dependent on multiple viral proteins and cellular pro-
cesses (Alwine, 2012; Buchkovich et al., 2008; Gibson, 2008;Wo-
mack and Shenk, 2010). Our findings reveal that pUL38 contrib-
utes to one or more of these events by ensuring that ELOVL7
synthesizes the lipids containing saturated VLCFA that are incor-
porated into the virion, in addition to its role in controlling cell sur-
vival (Qian et al., 2011; Savaryn et al., 2013; Terhune et al., 2007).
Healthy primary fibroblasts have a low level of ELOVL7
expression (Janssen et al., 2009; Figures 2A and 3A); we showed1382 Cell Reports 10, 1375–1385, March 3, 2015 ª2015 The Authorsthat efficient HCMV replication in fibroblast cells requires
ELOVL7 expression and activity. HMCV has broad cellular
tropism and tissue distribution during acute infection (Mocarski
et al., 2007), and one question raised by our results is: are tissues
that express ELOVL7 more susceptible to HCMV infection? In
one case of fatal congenital infection, HCMV-infected cells
were found in tissues that also express ELOVL7, such as the
pancreas, kidneys, and liver (Bissinger et al., 2002; Ohno et al.,
2010). However, the lungs were a key target for HCMV infection,
even though ELOVL7 expression in normal lung tissue was only
faintly detected (Ohno et al., 2010). Based on our findings, we
would predict that ELOVL7 expression in the lungs would in-
crease upon infection, resulting in greater cellular susceptibility
to viral replication.
We propose amodel for the steps of viral replication leading to
the synthesis of the specialized lipids that are incorporated into
virions (Figure 7). pUL38 is expressed with early kinetics, allow-
ing for mTOR signaling by preventing the block that would other-
wise be introduced by the tuberous sclerosis protein complex
(Moorman et al., 2008). Subsequently, mTOR stimulates the
activity of SREBPs whose mature forms migrate from the ER to
the nucleus to upregulate ELOVL7 gene expression. Additional
downstream processes may also be influenced by mTOR,
such as translation of ELOVL7 mRNA. Although mTOR inhibition
strongly blocks ELOVL7 protein induction, there is a modest in-
duction in the presence of Torin 2 (Figure 5B) and a pUL38-defi-
cient virus can induce the elongase to a limited extent (Figure 6B).
These observations argue that a second additional pathway—a
pUL38- and/or mTOR-independent pathway—also contributes
to the elevated ELOVL7 accumulation induced by HCMV. The
viral factor(s) responsible for this redundant pathway awaits
identification, but, because ELOVL7 levels are increased by
24 hpi (Figures 2A and 3A), it is likely that these additional viral
factor(s) are expressed with immediate-early or early kinetics.
It is unclear whether the pUL38/mTOR-independent pathway
also requires SREBP maturation or relies on other cellular fac-
tors such as carbohydrate-response element-binding protein
(ChREBP), PKR-like ER kinase (PERK), or viperin that may
contribute to the control of lipogenesis during HCMV replication
(Seo andCresswell, 2013; Yu et al., 2013, 2014). The observation
that HCMV utilizes multiple mechanisms to stimulate ELOVL7
expression highlights the critical role of its activity to produce
the VLCFAs that are required for viral replication.
ELOVL5 is also required to produce a maximal virus yield (Fig-
ure 2B). This elongase produces polyunsaturated FAs (PUFAs)
(Leonard et al., 2002; Ohno et al., 2010). Our FA analyses reveal
that, although some PUFAs that may be produced by ELOVL5
were labeled (Figure S1A), they are only a minor constituent in
the virion envelope (Figure S1B). Thus, ELOVL5 might not func-
tion to optimize lipid FA substituents in virus particles. Rather,
it could counteract virus-induced cell stress. HCMV infection
triggers various host cellular stresses (Alwine, 2008; Qian et al.,
2011), and saturated VLCFAs, such as those elevated by
HCMV, can induce an ER-stress response (Deguil et al., 2011;
Karaskov et al., 2006). Indeed, exogenous C26:0 modestly in-
hibited the production of HCMV (Figure S2F), possibly through
an elevated cell stress response. PUFAs, such as those pro-
duced by ELOVL5, aid in limiting the effect of cellular stresses
(Pineau et al., 2009). Further studies are required to delineate the
role of ELOVL5 during HCMV replication.
Overall, our results demonstrate that HCMV infection dramat-
ically induces the accumulation of ELOVL7 to synthesize lipids
with saturated VLCFAs required for the production of infectious
progeny. Furthermore, HCMV employs multiple mechanisms to
ensure that ELOVL7 is expressed in fibroblast cells. Although
the HCMV envelopment process remains largely a mystery,
this work reveals the contribution of three host factors—
mTOR, SREBP1, and ELOVL7—and one viral factor, pUL38, to
the construction of a functional virion. Our HCMV results high-
light the need to study the role of FA elongation and ELOVLs in
the replication of other viruses to understand how enveloped
viruses interact with host cells to ensure the generation of a lipid
environment that favors viral progeny production.
EXPERIMENTAL PROCEDURES
Cells, Virus, and Experimental Setup
Human lung fibroblast cells, MRC-5, cultured in DMEM containing 10% FBS
were used in this study. For experiments involving infection, cells were main-
tained at confluence for 3 days and switched to DMEM without serum 1 day
prior to infections. HCMV virus stocks of strain AD169 were made by clarifying
themedium fromMRC-5 cells via BAD, a bacterial artificial chromosome (BAC)
expressing the AD169 genome (Yu et al., 2002), followed by pelleting through
20% sorbitol and resuspending in serum-free DMEM. For viral envelope
analysis, virions were prepared by further purification through two sequential
sodium tartrate gradients (Liu et al., 2011b). Virus titers were determined
using tissue culture infectious dose (TCID50). Relative IUs were assessed
using an anti-pUL123 (IE1) monoclonal antibody (clone 1B12) followed by
visualization using an anti-mouse Alexa 488 secondary antibody (Jackson
ImmunoResearch) and quantified using an Operetta Instrument (Perkin-Elmer)
as previously described (Grady et al., 2013; Terry et al., 2012). Virus lacking the
UL38 gene was generated using the ADdlUL38 BAC (Terhune et al., 2007).
Because the ADdlUL38 virus shows a limited cytopathic effect, the viral stocks
for this mutant virus were determined by methanol fixing the cells on the
TCID50 plates and then staining them using the anti-pUL123 antibody followed
by a fluorescent secondary antibody to visualize infected cells. For 13C-label-
ing experiments, following infection, the cells were grown in DMEM containing
uniformly carbon-labeled glucose (Cambridge Isotopes) at 4.5 g/l. Particle-to-
TCID-IU ratio was assayed by quantitating viral DNA using UL123-specific
primers (Womack and Shenk, 2010).
MRC-5 cells expressing pUL38 and ELOVL7 from an EF1a promoter were
generated by cloning the UL38 gene from BAD and ELOVL7 cDNA (GenBank
accession number BC130310; Open Biosystems) into the pLVX-EF1a vector
(Clontech). The cloned plasmids, along with psPAX2 and MD.2G plasmids
(Addgene plasmids 12259 and 12260) were used to generate lentiviral
particles for stable expression of the protein of interest in fibroblasts. Following
lentiviral treatment, the cells were selected using 2 mg/ml puromycin. As a con-
trol, cells that expressed GFP from the pLVX-EF1a plasmid were generated in
parallel.
The following mTOR inhibitors were used in this study: Torin 2 (50 and
100 nm; Tocris Biosciences), INK128 (500 nM; Cayman Chemicals), and
PP242 (1 mM; Tocris Biosciences). For all experiments utilizing inhibitors, the
medium was replaced at 48 hpi to replenish the compound being examined.
Cell viability was determined using AQueous One (Promega).
FA Analysis
Lipid extraction and FA analysis were performed as previously described
(Koyuncu et al., 2013). Briefly, cells and virions were lysed using pre-chilled
50%methanol containing 0.05 M HCl. Chloroform was added to extract lipids
followed by saponification and isolation of the liberated FAs tails. The FAswere
analyzed by liquid-chromatography-coupled high-resolution mass spectrom-
etry (LC-MS) (Kamphorst et al., 2011; Koyuncu et al., 2013). Two LC-MSCemethods were employed. To analyze all FAs, the samples were run on a
Luna C8 reversed-phase column (Phenomemex) on a gradient from buffer A
(97:3 water:methanol with 10 mM tributylamine and 15 mM acetic acid [pH
4.5]) to buffer B (100% methanol) during a 50-min run time. For low abundant
FAs (C22–30), the samples were concentrated 5-fold and analyzed using a
similar gradient during a 40-min run time that excluded the shorter chain,
more abundant FAs (e.g., %C20). Both methods utilized a Thermo Exactive
orbitrap mass spectrometer running in negative mode to identify and measure
each FA species. MS data were analyzed using MAVEN: Metabolomic
Analysis and Visualization Engine (Clasquin et al., 2012; Melamud et al.,
2010) and MATLAB (The MathWorks). For labeling experiments, the results
were corrected for naturally occurring carbon-13 (Munger et al., 2008).
Reduction of ELOVL Activity
Gene knockdown of ELOVLswas achieved by shRNA. Lentiviral particles were
generated in 293T cells following transfection of pLKO.1-puro clones targeting
ELOVL1–7 or a non-targeting (NT) control (Sigma), pMD.2G, and psPAX2.
Transduced MRC-5 cells were selected by 2 mg/ml puromycin for 4 days
and allowed to grow for 2 days without puromycin prior to being used in an
experiment. Table S1 contains information regarding shRNA clones.
Protein and mRNA Analysis
Proteins were examined by western blot. Primary antibodies used are listed in
the supplement (Table S3). All blots were blocked using 5%BSA in a Tris-buff-
ered saline with 0.05% tween-20 (TBS-T), except rabbit anti-ELOVL7 blots,
which were blocked in 5% milk in TBS-T. For RNA isolation, cells were lysed
using Trizol followed by purification using a Direct-zol kit (Zymo Research).
mRNA was converted to cDNA via reverse transcription using an oligo-dT
primer and 1 or 2 mg of total RNA (Taqman; Life Technologies). Levels were
measured by real-time qPCR using SYBR Green (Life Technologies). Table
S2 lists the sequences for all primers used in this study.
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